UK Companies House feature
AMICUS THERAPEUTICS UK LIMITED
Profile
- Company number
- 05541527
- Status
- Active
- Incorporation
- 2005-08-19
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 86900
- Hubs
- UK Healthcare
Accounts
Pending extraction
No iXBRL extracted yet for this company.
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Ernst & Young LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“Corporate support letters have been issued by Amicus Therapeutics Inc. which itself prepares and files financial statements on the going concern basis. Further detail on going concern is contained in section 2.2 of Notes to the Financial Statements.”
Subsidiaries
- Amicus Therapeutics GmbH · 100% held · Germany · Commercialisation of Galafold and PomOp
- Amicus Therapeutics KK (Japan) · 100% held · Japan · Commercialisation of Galafold
- Amicus Therapeutics BV · 100% held · Amsterdam, Netherlands · Commercialisation of Galafold
- Amicus Therapeutics SAS · 100% held · France · Commercialisation of Galafold
- Amicus Therapeutics S.r.l · 100% held · Italy · Commercialisation of Galafold and PomOp
- Amicus Therapeutics SP · 100% held · Spain · Commercialisation of Galafold and PomOp
- Amicus Therapeutics Canada Inc. · 100% held · Canada · Commercialisation of Galafold
- Amicus Therapeutics Pty Ltd · 100% held · Australia · Commercialisation of Galafold
- Amicus Therapeutics ApS · 100% held · Copenhagen, Denmark · Commercialisation of Galafold
- Amicus Therapeutics Europe Limited · 100% held · Ireland · Commercialisation of Galafold and PomOp
- Amicus Therapeutics Switzerland GmbH · 100% held · Switzerland · Commercialisation of Galafold
- Amicus Therapeutics UK Operations Limited · 100% held · UK · Commercialisation of Galafold
- Amicus Therapeutics France Services SAS Limited · 100% held · France · Commercialisation of Galafold
Significant events
- “Effective 1st January 2024, the Company licenses the intellectual property rights associated with the manufacture, use, and sale of Galafold outside the US. It manages the supply chain for the international market undertaking key activities, including commercialization of Galafold in the international market.”
- “From August 2023 the Company is the UK Marketing Authorisation Holder for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat).”
- “Revenue increase was driven by FY24 being the first full year of PomOp sales and continued growth of Galafold sales.”
- “In October 2023 Amicus Therapeutics Inc. entered into a loan agreement with Blackstone for $400m in order to repay existing group debt and provide adequate working capital for the future. As part of this agreement Amicus Therapeutics UK Limited provided a first lien security interest over cash held in its bank account and its trade debtor balances.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
4 active · 30 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ARNOLD, Stephen | Director | 2024-03-27 | Aug 1969 | British |
| GREEN, Steven John | Director | 2020-06-01 | Apr 1977 | British |
| JONES, Adam | Director | 2022-07-29 | May 1972 | British |
| STOCKWELL, Caroline Amelia | Director | 2022-07-29 | Nov 1966 | British |
Show 30 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BREW, Emma Rose | Secretary | 2021-04-01 | 2021-08-27 |
| CROWLEY, John Francis | Secretary | 2005-10-25 | 2016-03-18 |
| GHYOOT, Geoffrey Marc Caroline | Secretary | 2016-03-18 | 2017-01-30 |
| GODRICH, Toby | Secretary | 2021-08-27 | 2022-07-04 |
| LICHOLAI, Gregory Peter, Dr | Secretary | 2005-08-19 | 2005-10-26 |
| REICHMAN, Nicole | Secretary | 2017-01-30 | 2021-04-01 |
| CHETTLEBURGHS SECRETARIAL LTD | Corporate Nominee Secretary | 2005-08-19 | 2005-08-19 |
| ALLSOP, David Stephen | Director | 2015-04-27 | 2017-12-31 |
| BAIRD, William Denise | Director | 2012-04-16 | 2018-12-31 |
| BECHTER, Mark | Director | 2016-03-18 | 2017-01-30 |
| BOUDES, Pol Francis | Director | 2010-12-09 | 2013-03-14 |
| CAMPBELL, Bradley Lewis | Director | 2016-03-18 | 2022-08-08 |
| CROWLEY, John Francis | Director | 2005-10-25 | 2016-03-18 |
| GHYOOT, Geoffrey Marc Caroline | Director | 2016-03-18 | 2017-03-10 |
| HUERTAS, Pedro Enrique, Dr | Director | 2005-08-19 | 2005-10-26 |
| ILETT, John Edward | Director | 2015-09-09 | 2015-10-07 |
| JORDAN, Simon Paul | Director | 2019-06-12 | 2024-01-29 |
| KIRK, John | Director | 2013-03-14 | 2016-03-18 |
| LICHOLAI, Gregory Peter, Dr | Director | 2005-08-19 | 2005-10-26 |
| MACALUSO, Peter Michael | Director | 2013-03-14 | 2013-10-18 |
| MACHIN, Jane Elizabeth | Director | 2017-03-21 | 2018-12-31 |
| MOCHAN, Lori Elizabeth | Director | 2018-05-03 | 2020-02-21 |
| PALLING, David John, Dr | Director | 2005-08-19 | 2005-10-26 |
| PATTERSON, Matthew Randolph | Director | 2005-10-25 | 2011-08-31 |
| QUIMI, Daphne Elke | Director | 2019-02-01 | 2024-01-29 |
| REES, Nicholas Alan | Director | 2020-10-01 | 2025-10-15 |
| REICHMAN, Nicole | Director | 2017-02-01 | 2021-04-01 |
| STOCKHAM, Ben Michael Paul | Director | 2018-05-03 | 2020-07-31 |
| WARUSZ, Joseph Michail | Director | 2005-10-25 | 2006-03-31 |
| WOLFF, Detlef | Director | 2018-05-03 | 2019-01-27 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Amicus Therapeutics International Holding Ltd | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-06-30 | Active |
Filing timeline
Last 20 of 128 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2025-10-24 | TM01 | officers | termination director company with name termination date |
| 2025-10-03 | AA | accounts | accounts with accounts type full |
| 2025-08-22 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-10-11 | AA | accounts | accounts with accounts type full |
| 2024-08-30 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-07-12 | AP01 | officers | appoint person director company with name date |
| 2024-01-30 | TM01 | officers | termination director company with name termination date |
| 2024-01-30 | TM01 | officers | termination director company with name termination date |
| 2024-01-03 | AA | accounts | accounts with accounts type full |
| 2023-12-19 | SH19 | capital | capital statement capital company with date currency figure |
| 2023-12-19 | SH20 | capital | legacy |
| 2023-12-19 | CAP-SS | insolvency | legacy |
| 2023-12-19 | RESOLUTIONS | resolution | resolution |
| 2023-11-22 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2023-11-21 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2023-10-23 | RESOLUTIONS | resolution | resolution |
| 2023-10-23 | MA | incorporation | memorandum articles |
| 2023-10-12 | MR04 | mortgage | mortgage satisfy charge full |
| 2023-10-09 | MR01 | mortgage | mortgage create with deed with charge number charge creation date |
| 2023-08-18 | CS01 | confirmation-statement | confirmation statement with no updates |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Credit score requires extracted accounts data.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory
Activity Score not yet computed for this company.